- Title:
Schedule One Update - Belluscura PLC - Time:
11:00:05 - Date:
21 May 2021 - Category:
Capital structure - ID:
4434Z
| ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") |
||||||||||||||||||
| |
||||||||||||||||||
| COMPANY NAME: |
||||||||||||||||||
| Belluscura plc ("Belluscura", the "Company") |
||||||||||||||||||
| COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : |
||||||||||||||||||
| Registered office: 15 Fetter Lane, London, EC4A 1BW Principal trading address: (Belluscura LLC) 5504 Democracy Drive (Suite 200), Plano, Texas, 75024, USA |
||||||||||||||||||
| COUNTRY OF INCORPORATION: |
||||||||||||||||||
| England and Wales
|
||||||||||||||||||
| COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: |
||||||||||||||||||
|
|
||||||||||||||||||
| COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: |
||||||||||||||||||
| Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter / more adaptable / have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia / COPD (i.e. asthma/ emphysema /chronic bronchitis) and other respiratory illnesses. It received 510(k) clearance from the US Food & Drug Administration (FDA) in March 2021 for its X-PLO₂R range of oxygen concentrators, which will be launched in 2021. The Company has a registered office in the UK. Its subsidiary, Belluscura LLC, is based in Plano, Texas, USA. The USA is the Company's main country of operation. |
||||||||||||||||||
| DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): |
||||||||||||||||||
| 113,240,735 ordinary shares of 1 pence each
|
||||||||||||||||||
| CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: |
||||||||||||||||||
| £17.5 million.
Anticipated market capitalisation: £50.96 million
|
||||||||||||||||||
| PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: |
||||||||||||||||||
| 40%
|
||||||||||||||||||
| DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED: |
||||||||||||||||||
| None
|
||||||||||||||||||
| FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): |
||||||||||||||||||
| THE BOARD Mr Adam Reynolds - Non-Executive Chairman Mr Robert (Bob) Michael Rauker - Chief Executive Officer Mr Anthony (Tony) Stephen Dyer - Chief Financial Officer Mr David John Poutney - Non-Executive Director Dr Patrick John Strollo Jr - Non-Executive Director Mr Richard (Ric) John Piper - Non-Executive Director
|
||||||||||||||||||
| FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): |
||||||||||||||||||
|
|
||||||||||||||||||
| NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: |
||||||||||||||||||
| N/A
|
||||||||||||||||||
| (i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: |
||||||||||||||||||
| (i) The current accounting reference date of the Company is 31 December. (ii) 31 December 2020 (iii) Accounts for 6 months period ending 30 June 2021 (to be notified by 30 September 2021); Accounts for 12 months period ending 31 December 2021 (by 30 June 2022); Accounts for 6 months period ending 30 June 2022 (by 30 September 2022).
|
||||||||||||||||||
| EXPECTED ADMISSION DATE: |
||||||||||||||||||
| 28 May 2021
|
||||||||||||||||||
| NAME AND ADDRESS OF NOMINATED ADVISER: |
||||||||||||||||||
| SPARK Advisory Partners Limited 5 St John's Lane Farringdon London EC1M 4BH
|
||||||||||||||||||
| NAME AND ADDRESS OF BROKER: |
||||||||||||||||||
| Dowgate Capital Limited 15 Fetter Lane London EC4A 1BW
|
||||||||||||||||||
| OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: |
||||||||||||||||||
| Copies of this document will be available free of charge to the public during normal business hours on any day (Saturdays, Sundays and public holidays excepted) at the offices of SPARK Advisory Partners, 5 St John's Lane, London, EC1M 4BH in accordance with the AIM Rules. This document will also be available for download from the Company's website at https://www.belluscura.com/.
|
||||||||||||||||||
| THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY |
||||||||||||||||||
| The QCA Corporate Governance Code, as published by the Quoted Companies Alliance.
|
||||||||||||||||||
| DATE OF NOTIFICATION: |
||||||||||||||||||
| 21 May 2021
|
||||||||||||||||||
| NEW/ UPDATE: |
||||||||||||||||||
| UPDATE
|
Schedule One Update - Belluscura PLC 11:00:0521 May 2021Capital structure4434Z